Circulating miRNA markers show promise as new prognosticators for multiple myeloma

[1]  A. Allegra,et al.  MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma , 2014, British journal of haematology.

[2]  Je-Jung Lee,et al.  Decreased body mass index is associated with poor prognosis in patients with multiple myeloma , 2014, Annals of Hematology.

[3]  S. Ševčíková,et al.  Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance , 2014, Haematologica.

[4]  Michael A. Freitas,et al.  In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation , 2013, The Journal of experimental medicine.

[5]  Roberta Galli,et al.  MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response , 2012, Proceedings of the National Academy of Sciences.

[6]  W. Tse,et al.  Mutation of STAT1/3 binding sites in gp130(FXXQ) knock-in mice does not alter hematopoietic stem cell repopulation or self-renewal potential. , 2012, American journal of stem cells.

[7]  Hajime Uno,et al.  Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. , 2011, Blood.

[8]  G. Morgan,et al.  Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[9]  M. Boccadoro,et al.  Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Kantarjian,et al.  Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.

[11]  Gabriele Sales,et al.  Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. , 2009, Blood.

[12]  M. Schemper,et al.  The estimation of average hazard ratios by weighted Cox regression , 2009, Statistics in medicine.

[13]  A. Neri,et al.  Integrative high‐resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles , 2009, Genes, chromosomes & cancer.

[14]  L. D. Barnes,et al.  Correlation of Fragile Histidine Triad (Fhit) Protein Structural Features with Effector Interactions and Biological Functions* , 2009, Journal of Biological Chemistry.

[15]  C. Croce,et al.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.

[16]  M. Goldsmith,et al.  STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. , 2006, Blood.

[17]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .